With the growing understanding of the molecular biology of the UPS, proteasome and DUB inhibition have proven to be attractive strategies for cancer therapy.27, 32 Importantly, in contrast to 20 S proteasome inhibitor, most of reported DUB inhibitors can specifically target one or several DUBs by which more specific and less toxic anticancer agents may be generated. The gene discussed is HMBS; the disease is cancer.